Cardinal Energy Group, Inc. (CEGX) got back in the green last Thursday after a few sharp corrections. CEGX stock has been rather volatile as of late, bouncing up and down for no apparent reason. Can the progress the company recently reported get it on the right track long term?
Although penny stocks' movements are usually hard to predict, getting a better look at CEGX's recent venture initiatives could help set the bar for the expectations on the company's......more
Yesterday, AccelPath, Inc. (ACLP) filed an 8-K with the SEC, announcing the company had entered into a securities purchase agreement with an entity called Village Tea Distributors, Inc. Under the agreement, ACLP will purchase 70% of the company's common stock and all of its series A preferred stock, thus making it a majority-owned subsidiary of AccelPath.
To finance the agreement, ACLP agreed to issue a newly designed series of convertible preferred......more
Solar Power, Inc. (SOPW) has been very outspoken in its recent venture initiatives. The company has put on a good effort to keep investors up-to-date with its ongoing expansion plans in the Asian market. As a result, SOPW stock has enjoyed a stable climb, approaching the $2.00 mark after yesterday's close at $1.87.
Solar Power has targeted a few large Asian markets, including Hong Kong, Mongolia, and Japan. SOPW announced entering into a private placement......more
Earth Science Tech, Inc. (ETST) jumped out of obscurity at the end of September last month. The company's initial success came about after its CEO Harvey Katz, PhD, was featured in a live video interview done by the Cannabis Financial Network. Mr. Katz talked about the company's initiative to establish positions as a producer of cannabidiol (CBD) rich products, targeting the bioceutical, health and wellness, sports and alternative medicine markets.
Advanced Cell Technology, Inc. (ACTC) registered an impressive increase in price in Wednesday's session, going from $6.83 to $7.97 on a volume of nearly 400 thousand shares trading hands. The success of ACTC stock came about after two of the company's clinical trials were published in the Lancet online platform.
The publication gave the Phase 1/2 of retinal pigment epithelium cells for the treatment of Stargardt's macular deneration a good evaluation.......more